Search research articles

お問い合わせ

JoVEについて

概要リーダーシップブログ JoVEヘルプセンター

著者向け

出版プロセス編集委員会範囲と方針査読よくある質問投稿

図書館員向け

推薦の声購読アクセスリソース図書館諮問委員会よくある質問

研究

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments アーカイブ

教育

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual 教員リソースセンター教員サイト

プライバシーポリシー

関連する概念動画

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...

Heart Failure I: Introduction

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え

Same author

Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy.

Nature cardiovascular research·2026

Same author

Frailty and Congestion in Patients with Heart Failure: Clinical Interaction and Prognostic Implications.

Journal of clinical medicine·2026

Same author

Repurposing polyamines to prevent life-threatening arrhythmias in Short QT Syndrome type 3.

Nature communications·2026

Same author

Telomere length dynamics do not predict subclinical atherosclerosis progression over a six-year period.

GeroScience·2026

Same author

MR-ProADM Predicts Mortality and Heart Failure Events in ATTR Cardiac Amyloidosis.

Circulation·2026

Same author

Impact of Lipoprotein(a) on Residual Cardiovascular Risk After an Acute Coronary Syndrome.

Journal of clinical medicine·2026

Search research articles

関連する実験動画

Updated: Sep 9, 2025

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

拡張性心筋病と進行性心不全のリスクにおける不律性遺伝子型

Nerea Mora-Ayestarán^1,2,3, Juan Pablo Ochoa⁴, Cristina Gómez-González^2,3,5,6,7

¹Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, Manuel de Falla 1, Majadahonda, 28222 Madrid, Spain.

European heart journal

|August 29, 2025

まとめ

高リスクの拡張性心筋病 (DCM) 遺伝子型を有する患者は,進行性心不全 (AHF) の増加に直面します. この発見は,突然の心臓死を予防する以外にも,DCM患者に対する適した治療法を示唆しています.

キーワード:

拡張性心筋病遺伝子心不全予測心臓発作による突然死

さらに関連する動画

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

関連する実験動画

Last Updated: Sep 9, 2025

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

科学分野:

心臓病科
遺伝学
心不全の研究

背景:

拡張性心筋病 (DCM) は様々なリスクを持つ遺伝的サブタイプがあります.
DCMにおける高リスクの不律性遺伝子型と進行性心不全 (AHF) の合併症の関連性は十分に理解されていません.

研究の目的:

高リスクの不律性遺伝子型を持つDCM患者で,AHFの発生頻度がより高いかどうかを調べる.
DCM遺伝子型とAHF合併症の関係を分析する.

主な方法:

遺伝子型DCM患者1203人を分析した.
患者は高リスクの不律性遺伝子型,TTN変種,その他の遺伝子変種,遺伝子型陰性グループに分類された.
主要エンドポイント: AHFイベントの複合 (デバイスの埋め込み,移植,死亡率); 二次エンドポイント:悪性心房不律症 (MVA).

主要な成果:

患者の15. 4%が高リスクの不律性遺伝子型でした.
高リスク遺伝子型の患者は,他のグループ (10. 1から18. 7%) と比較して AHFの発生率が著しく高かった.
高リスクの不律性遺伝子型はAHFとMVAの独立した予測因子でした.

結論:

高リスクの不律性遺伝子型を持つDCM患者は,AHFイベントのより大きな負担を経験します.
これらの発見は,この患者のサブグループに対して,不律症の管理を超えた明確な治療戦略の必要性を支持する.